Onco-pneumology

Charlotte Germonpré is the study coordinator for the Pneumology Department.

Charlotte Germonpré

Telephone: +32 9 246 84 40

Email address: charlotte.germonpre@mijnziekenhuis.be

More information about Charlotte Germonpré

The Oncology-Pneumology Study Department is under the leadership of:

Dr Lamont Jan

More information about Dr Lamont Jan

Prof. Dr Germonpré Paul

More information about Prof. Dr Germonpré Paul

• DeLLphi-303 study: A phase 1b study evaluating the safety and efficacy of first-line treatment with tarlatamab in combination with carboplatin, etoposide and a PD-L1 inhibitor in subjects with extensive-stage small cell lung carcinoma. Read more here.

• Immuno-MESODEC study: Addition of the checkpoint inhibitor atezolizumab and dendritic cell therapy to standard chemotherapy treatment for patients with malignant pleural mesothelioma. Read more here.

• M18-868 study: Open-label, randomised, controlled, global phase 3 trial of telisotuzumab vedotin (ABBV-399) versus docetaxel in patients with previously treated c-Met overexpressing, EGFR wild-type, locally advanced and metastatic non-squamous cell non-small cell lung cancer. Read more here.

• NeoCOAST-2 study: A multi-centre, open-label, randomised phase II trial of neoadjuvant and adjuvant treatment in patients with resectable non-small cell lung cancer at early stages (II to IIIB). Read more here.

• Tropion-08 study: A randomised, open-label phase-III trial of Dato-DXd plus Pembrolizumab versus Pembrolizumab in previously untreated patients who have advanced or metastatic PD-L1-high (TPS ≥50%) non-small cell lung cancer without actionable genomic alterations. Read more here.